- Home
- JLS vs GNLX Comparison
JLS vs GNLX Comparison
Compare JLS & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLS
- GNLX
- Stock Information
- Founded
- JLS 2009
- GNLX 2001
- Country
- JLS United States
- GNLX United States
- Employees
- JLS N/A
- GNLX N/A
- Industry
- JLS Investment Managers
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- JLS Finance
- GNLX Health Care
- Exchange
- JLS Nasdaq
- GNLX Nasdaq
- Market Cap
- JLS 102.7M
- GNLX 184.4M
- IPO Year
- JLS N/A
- GNLX 2023
- Fundamental
- Price
- JLS $19.04
- GNLX $3.54
- Analyst Decision
- JLS
- GNLX Strong Buy
- Analyst Count
- JLS 0
- GNLX 4
- Target Price
- JLS N/A
- GNLX $18.25
- AVG Volume (30 Days)
- JLS 26.6K
- GNLX 201.9K
- Earning Date
- JLS 01-01-0001
- GNLX 03-31-2025
- Dividend Yield
- JLS 9.33%
- GNLX N/A
- EPS Growth
- JLS N/A
- GNLX N/A
- EPS
- JLS N/A
- GNLX N/A
- Revenue
- JLS N/A
- GNLX $8,000.00
- Revenue This Year
- JLS N/A
- GNLX N/A
- Revenue Next Year
- JLS N/A
- GNLX N/A
- P/E Ratio
- JLS N/A
- GNLX N/A
- Revenue Growth
- JLS N/A
- GNLX N/A
- 52 Week Low
- JLS $15.48
- GNLX $1.60
- 52 Week High
- JLS $17.97
- GNLX $7.04
- Technical
- Relative Strength Index (RSI)
- JLS 59.65
- GNLX 45.34
- Support Level
- JLS $18.87
- GNLX $3.51
- Resistance Level
- JLS $19.25
- GNLX $4.37
- Average True Range (ATR)
- JLS 0.17
- GNLX 0.45
- MACD
- JLS -0.00
- GNLX -0.13
- Stochastic Oscillator
- JLS 58.33
- GNLX 22.95
About JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The Fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. Its investment objective to generate high current income through opportunistic investments in securitized credit.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.